Business ❯ Biotechnology ❯ Pharmaceuticals

Drug Development

Clinical Trials Antibody-Drug Conjugates Autoimmune Diseases AI in Drug Discovery Obesity Treatments FDA Approvals Efficacy and Safety Results New Drug Application Vepdegestrant Eli Lilly and Company

Evotec Leans Into Biologics as Horizon Overhaul Sets 2026 Reset

Management signals a reset year powered by biologics growth plus milestone income.

SCYNEXIS Acquires Poxel’s PXL-770 for ADPKD, Plans 2026 Phase 2 Trial

Novartis to Acquire Excellergy in Up to $2 Billion Deal for Next-Gen Anti-IgE

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Vertex Heads Into Feb. 12 Earnings With Cautious Market After Mixed Year

Biogen Guides 2026 Profit Above Estimates on Cost Cuts and Leqembi Momentum

Lilly, Repertoire Strike Up-to-$1.93 Billion Autoimmune Drug Pact

Genentech Lifts Holly Springs Biomanufacturing Plan to $2 Billion, Over 500 Jobs

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Sanofi, Dren Bio Set Autoimmune Collaboration Worth Up to $1.7 Billion With $100 Million Upfront

Phrontline Biopharma Raises $60 Million as Samsung Deepens ADC Push

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

Takeda and Nabla Bio Expand AI Protein-Design Deal With Potential Payouts Above $1 Billion

aTyr Faces Securities Suit After Phase 3 Failure Triggers 83% Stock Crash

Lilly Steps Up Obesity Push With San Diego Innovation Hub and $6.5 Billion Houston Factory

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

Acadia Halts Carbetocin for Prader-Willi After Phase 3 Miss

ATyr’s Sarcoidosis Drug Fails Phase 3 Goal, Shares Plunge Over 80%